AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well AKT inhibitor MK-2206 works in treating patients
with relapsed or refractory acute myeloid leukemia (AML). AKT inhibitor MK-2206 may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth.